Quick Answer
Avalo Therapeutics, Inc. reported Net Income of -$78.26 million for fiscal year 2025.
Avalo Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$78.26M | -122.8% |
| 2024 | -$35.13M | -11.4% |
| 2023 | -$31.54M | +24.3% |
| 2022 | -$41.66M | +50.6% |
| 2021 | -$84.38M | -32.9% |
| 2020 | -$63.50M | -295.1% |
| 2019 | -$16.07M | +59.9% |
| 2018 | -$40.05M | -437.4% |
| 2017 | $11.87M | +172.1% |
| 2016 | -$16.47M | -57.0% |
| 2015 | -$10.49M | +34.7% |
| 2014 | -$16.06M | -23.1% |
| 2013 | -$13.05M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$30.62M | -232.9% | -47.5% |
| June 30, 2025 | -$20.77M | -121.1% | -57.9% |
| March 31, 2025 | -$13.15M | +89.2% | -157.1% |
| September 30, 2024 | $23.04M | +540.6% | -76.6% |
| June 30, 2024 | $98.46M | +1301.8% | +181.2% |
| March 31, 2024 | -$121.29M | -1118.4% | -2220.0% |
| September 30, 2023 | -$5.23M | -263.8% | +36.2% |
| June 30, 2023 | -$8.19M | +36.9% | +17.7% |
- Avalo Therapeutics, Inc. showed a decrease of -122.8% in Net Income compared to the prior fiscal year.
- Over the 2013–2025 period, Avalo Therapeutics, Inc.’s net income has declined by 499.9% (from -$13.05 million to -$78.26 million).
- The most recent figure is from Avalo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: